Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC)

Radwan Massoud, MD, Rita Assi, MD, Elie Fares, Nabila Kreidieh, Rami Mahfouz, Souha Kanj, Aline El-Zakhem, Mohamed A. Kharfan-Dabaja, MD, Ali Bazarbachi, MD PhD, Jean El Cheikh, MD PhD

Blood (2016) 128 (22): 5824.

https://doi.org/10.1182/blood.V128.22.5824.5824

Published: 2016

Journal Articles

Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML

Jean El Cheikh, MD PhD, Radwan Massoud, Elie Fares, Nabila Kreidieh, Rami Mahfouz, Mohamed A Kharfan-Dabaja, MD, Ali Bazarbachi, MD PhD

Blood (2016) 128 (22): 5872.

https://doi.org/10.1182/blood.V128.22.5872.5872

Published: 2016

Journal Articles

Pretransplantation Myeloablative Conditioning Regimen with Intravenous Busulfan Dose Adjustment for Older Patients with Hematologic Malignancies

Sabine Fürst, MD, Jean El Cheikh, MD PhD, Bénédicte Devictor, MD, Sandra Cournier, Angela Granata, MD, Samia Harbi, MD, Raynier Devillier, MD PhD, Faezeh Legrand, MD, Stefania Bramanti, MD, Claude Lemarie, PharmD, Jean Pierre Weiller, MD, Catherine Faucher, MD, Christian Chabannon, MD PhD, Borje S. Andersson, MD PhD, Didier Blaise, MD PhD

Blood (2016) 128 (22): 5751.

https://doi.org/10.1182/blood.V128.22.5751.5751

Published: 2016

Journal Articles

Post Transplant Brentuximab Maintenance Appears More Effective Than Post Transplant Salvage Brentuximab for Relapsed/Refractory Hogkin's Lymphoma

Amanda Chidiac, Radwan Massoud, MD, Mohamad Haidar, Elie Fares, Ali Bazarbachi, MD PhD, Jean El Cheikh, MD PhD

Blood (2016) 128 (22): 5357.

https://doi.org/10.1182/blood.V128.22.5357.5357

Published: 2016

Journal Articles

Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant

Rana Salem, MD, Radwan Massoud, MD, Rami Mahfouz, Ali Bazarbachi, MD PhD, Jean El Cheikh, MD PhD

Blood (2016) 128 (22): 5238.

https://doi.org/10.1182/blood.V128.22.5238.5238

Published: 2016

Journal Articles

Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

Blood (2016) 128 (22): 4624.

https://doi.org/10.1182/blood.V128.22.4624.4624

Published: 2016

Journal Articles

The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.

Roberto Crocchiolo, MD PhD, Sabine Fuerst, MD, Jean El-Cheikh, MD PhD, Angela Granata, Claire Oudin, Geoffroy Venton, Norbert Vey, Reda Bouabdallah, MD, Anne Marie Stoppa, Florence Broussais, MD, Aude Charbonnier, MD, PhD, Claude Lemarie, Diane Coso, MD, Thomas Prebet, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 3029.

https://doi.org/10.1182/blood.V120.21.3029.3029

Published: 2012

Journal Articles

LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.

Sabine Furst, MD, Roberto Crocchiolo, MD PhD, Jean El-Cheikh, MD PhD, Catherine Faucher, MD, Claire Oudin, Angela Granata, Geoffroy Venton, Claude Lemarie, Diane Coso, MD, Reda Bouabdallah, MD, Anne Marie Stoppa, Norbert Vey, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 3031.

https://doi.org/10.1182/blood.V120.21.3031.3031

Published: 2012

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Jean El-Cheikh, MD PhD, Stéphane Morisset, Stat., Anne Sirvent, MD, Oumedaly Reman, MD, Jérôme Cornillon, MD, Reza Tabrizi, MD, Noel Milpied, MD, Jean-Luc Harousseau, MD, Hélène Labussière-Wallet, MD, Franck E. Nicolini, MD, PhD, Charles Dumontet, M. D., Ph.D., Mohamad Mohty, Michel Attal, MD, Didier Blaise, MD, Philippe Moreau, MD, Hervé Avet-Loiseau, MD, PhD

Blood (2012) 120 (21): 3116.

https://doi.org/10.1182/blood.V120.21.3116.3116

Published: 2012

Journal Articles

NK Cells Display Poor Anti Lymphoma and AML Function At Early Times Following Allogenic HLA-Identical SCT for Leukemia and Lymphomas.

Daniel Olive, MD, PhD, Caroline Pical, Jean El-Cheikh, MD PhD, Roberto Crocchiolo, MD, Sabine Furst, MD, Didier Blaise, MD, Cyril Fauriat

Blood (2012) 120 (21): 3045.

https://doi.org/10.1182/blood.V120.21.3045.3045

Published: 2012

Journal Articles

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus On Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Jean El-Cheikh, MD PhD, Raynier Devillier, Roberto Crocchiolo, MD PhD, Sabine Furst, MD, Boris Calmels, Catherine Faucher, Anne Marie Stoppa, MD, Angela Granata, Claire Oudin, Patrick Ladaique, Claude Lemarie, Geoffroy Venton, Reda Bouabdallah, MD, Christine Zandotti, Pierre Berger, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 4496.

https://doi.org/10.1182/blood.V120.21.4496.4496

Published: 2012

Journal Articles

Efficacy and Safety of Micafungin for Prophylaxis of Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplant

Jean El-Cheikh, MD PhD, Geoffroy Venton, Roberto Crocchiolo, MD PhD, Sabine Furst, MD, Catherine Faucher, Angela Granata, Claire Oudin, Reda Bouabdallah, MD, Norbert Vey, MD, Segolene Duran, Pierre Berger, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 4505.

https://doi.org/10.1182/blood.V120.21.4505.4505

Published: 2012

Journal Articles

High Response RATE and NO Treatment Related Mortality After Brentuximab Vedotin Salvage Therapy Followed by Reduced Intensity Conditioning Regimen Allogeneic STEM CELL Transplantation (RIC-ALLO) in Patients with CD 30+ Lymphomas

Sabine Furst, MD, Reda Bouabdallah, MD, Diane Coso, MD, Roberto Crocchiolo, MD PhD, Jean El-Cheikh, MD PhD, Catherine Faucher, MD, Angela Granata, Claire Oudin, Geoffroy Venton, Anne Marie Stoppa, Claude Lemarie, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 4526.

https://doi.org/10.1182/blood.V120.21.4526.4526

Published: 2012

Journal Articles

Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial

Mohamad Mohty, Didier Blaise, MD, Myriam Labopin, Noel Milpied, MD, Sabine Furst, MD, Reza Tabrizi, MD, Thierry Guillaume, Stephane Vigouroux, MD, Jean El-Cheikh, MD PhD, Jacques Delaunay, MD, Steven Legouill, MD PhD, Philippe Moreau, MD, Patrice Chevallier, MD

Blood (2012) 120 (21): 1926.

https://doi.org/10.1182/blood.V120.21.1926.1926

Published: 2012

Journal Articles

Risk Factors of GANCICLOVIR–RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients

Geoffroy Venton, Roberto Crocchiolo, MD PhD, Jean El-Cheikh, MD PhD, Sabine Furst, MD, Angela Granata, Claire Oudin, Catherine Faucher, Diane Coso, MD, Reda Bouabdallah, MD, Pierre Berger, Norbert Vey, Patrick Ladaique, Christian Chabannon, MD, PhD, Michele Merlin, Didier Blaise, MD

Blood (2012) 120 (21): 4186.

https://doi.org/10.1182/blood.V120.21.4186.4186

Published: 2012

Journal Articles

Outcome After 9/10 Mismatched Unrelated Donor or Cord Blood Cells Allogeneic Stem Cell Transplantation (allo-SCT) in the Setting of Reduced-Intensity Conditioning (RIC)

Florent Malard, Sabine Furst, MD, Marion Loirat, Patrice Chevallier, MD, Jean El-Cheikh, MD PhD, Thierry Guillaume, MD, Jacques Delaunay, MD, Steven Legouill, MD PhD, Philippe Moreau, MD, Didier Blaise, MD, Mohamad Mohty, MD PhD

Blood (2012) 120 (21): 956.

https://doi.org/10.1182/blood.V120.21.956.956

Published: 2012

Journal Articles

Allogeneic Stem Cell Transplantation From Matched Related Donor in Patients Over the Age of 55 Years: A Prospective Multicenter Phase II Study of a Reduced Intensity Conditioning Associating Fludarabin-IV Busulfan and Thymoglobulin

Didier Blaise, MD, Mohamad Mohty, Noel Milpied, MD, Anne Gaelle Lecorroller, PhD, Nathalie Fegueux, Sabine Furst, MD, Patrice Chevallier, MD, Reza Tabrizi, MD, Mauricette Michallet, MD, PhD, Jean Yves Cahn, MD, Anne Sirvent, MD, Jacques-Olivier Bay, MD, PhD, Jean El Cheikh, MD, PhD, Catherine Faucher, MD, Roberto Crocchiolo, MD, Agnes Boyer-Chamard, MD, Luca Castagna, MD, Jean Marie Boher, PhD

Blood (2011) 118 (21): 1952.

https://doi.org/10.1182/blood.V118.21.1952.1952

Published: 2011

Journal Articles

Fertility in Female Patients After Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioning (RIC allo-SCT)

Emmanuelle Assouline, Roberto Crocchiolo, MD, Thomas Prebet, MD, PhD, Sabine Furst, MD, Jean El-Cheikh, MD PhD, Broussais Florence, Diane Coso, MD, Aude Charbonnier, Christian Chabannon, MD, PhD, Norbert Vey, MD, Gamerre Marc, Didier Blaise, MD, Blandine Courbiere

Blood (2011) 118 (21): 3057.

https://doi.org/10.1182/blood.V118.21.3057.3057

Published: 2011

Journal Articles

Impact of the New Anti-Myeloma Drugs on Outcome of Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High-Risk Multiple Myeloma

Jean El-Cheikh, MD PhD, Roberto Crocchiolo, MD, Jean Marie Boher, PhD, Sabine Furst, MD, Anne Marie Stoppa, Catherine Faucher, MD, Luca Castagna, MD, Angela Granata, Claire Oudin, jean Marc schiano De Colella, Diane Coso, MD, Reda Bouabdallah, MD, Didier Blaise, MD

Blood (2011) 118 (21): 4456.

https://doi.org/10.1182/blood.V118.21.4456.4456

Published: 2011

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma: Comparative Analysis of Outcomes Between Unrelated and Related Donor

Jean El-Cheikh, MD PhD, Sabine Furst, MD, Anne Marie Stoppa, Roberto Crocchiolo, MD, Catherine Faucher, MD, Luca Castagna, MD, Angela Granata, Claire Oudin, Patrick Ladaique, Boris Calmels, Claude Lemarie, jean Marc schiano De Colella, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2011) 118 (21): 4513.

https://doi.org/10.1182/blood.V118.21.4513.4513

Published: 2011

NARROW

Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC)

Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML

Pretransplantation Myeloablative Conditioning Regimen with Intravenous Busulfan Dose Adjustment for Older Patients with Hematologic Malignancies

Post Transplant Brentuximab Maintenance Appears More Effective Than Post Transplant Salvage Brentuximab for Relapsed/Refractory Hogkin's Lymphoma

Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant

Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.

LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.

Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.

NK Cells Display Poor Anti Lymphoma and AML Function At Early Times Following Allogenic HLA-Identical SCT for Leukemia and Lymphomas.

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus On Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Efficacy and Safety of Micafungin for Prophylaxis of Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplant

High Response RATE and NO Treatment Related Mortality After Brentuximab Vedotin Salvage Therapy Followed by Reduced Intensity Conditioning Regimen Allogeneic STEM CELL Transplantation (RIC-ALLO) in Patients with CD 30+ Lymphomas

Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial

Risk Factors of GANCICLOVIR–RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients

Outcome After 9/10 Mismatched Unrelated Donor or Cord Blood Cells Allogeneic Stem Cell Transplantation (allo-SCT) in the Setting of Reduced-Intensity Conditioning (RIC)

Allogeneic Stem Cell Transplantation From Matched Related Donor in Patients Over the Age of 55 Years: A Prospective Multicenter Phase II Study of a Reduced Intensity Conditioning Associating Fludarabin-IV Busulfan and Thymoglobulin

Fertility in Female Patients After Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioning (RIC allo-SCT)

Impact of the New Anti-Myeloma Drugs on Outcome of Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High-Risk Multiple Myeloma

Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma: Comparative Analysis of Outcomes Between Unrelated and Related Donor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only